[go: up one dir, main page]

WO2014195849A3 - Compositions and methods for the treatment of cerebrovascular diseases - Google Patents

Compositions and methods for the treatment of cerebrovascular diseases Download PDF

Info

Publication number
WO2014195849A3
WO2014195849A3 PCT/IB2014/061892 IB2014061892W WO2014195849A3 WO 2014195849 A3 WO2014195849 A3 WO 2014195849A3 IB 2014061892 W IB2014061892 W IB 2014061892W WO 2014195849 A3 WO2014195849 A3 WO 2014195849A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
treatment
compositions
cerebral
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2014/061892
Other languages
French (fr)
Other versions
WO2014195849A2 (en
Inventor
Mahesh Kandula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellix Bio Pvt Ltd
Original Assignee
Cellix Bio Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Pvt Ltd filed Critical Cellix Bio Pvt Ltd
Publication of WO2014195849A2 publication Critical patent/WO2014195849A2/en
Publication of WO2014195849A3 publication Critical patent/WO2014195849A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the compounds of formula I, formula II and formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II or formula III, and methods for the treatment of cerebrovascular diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of acute and chronic cerebral metabolic- vascular disorders (cerebral arteriosclerosis, thrombosis and cerebral embolism, transitory cerebral ischaemia).
PCT/IB2014/061892 2013-06-03 2014-06-02 Compositions and methods for the treatment of cerebrovascular diseases Ceased WO2014195849A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2432CH2013 2013-06-03
IN2432/CHE/2013 2013-06-03

Publications (2)

Publication Number Publication Date
WO2014195849A2 WO2014195849A2 (en) 2014-12-11
WO2014195849A3 true WO2014195849A3 (en) 2015-07-30

Family

ID=52008663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/061892 Ceased WO2014195849A2 (en) 2013-06-03 2014-06-02 Compositions and methods for the treatment of cerebrovascular diseases

Country Status (1)

Country Link
WO (1) WO2014195849A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4843073A (en) * 1986-06-25 1989-06-27 Farmitalia Carlo Erba S.P.A. 1-t-butyl ergolines useful in the treatment of cerebral insufficiency and senile dementia
US4870179A (en) * 1984-08-07 1989-09-26 Inverni Della Beffa Spa Process for preparing lysergol derivatives
US4980475A (en) * 1984-03-27 1990-12-25 I D B Holding S.P.A. Process for the preparation of N-10 alpha-methoxyl-lumilysergol and esters, thereof, and intermediates for their preparation
US20070060604A1 (en) * 2002-03-25 2007-03-15 Council Of Scientific And Industrial Research Antibiotic pharmaceutical composition with lysergol as bio-enhancer and method of treatment

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980475A (en) * 1984-03-27 1990-12-25 I D B Holding S.P.A. Process for the preparation of N-10 alpha-methoxyl-lumilysergol and esters, thereof, and intermediates for their preparation
US4870179A (en) * 1984-08-07 1989-09-26 Inverni Della Beffa Spa Process for preparing lysergol derivatives
US4843073A (en) * 1986-06-25 1989-06-27 Farmitalia Carlo Erba S.P.A. 1-t-butyl ergolines useful in the treatment of cerebral insufficiency and senile dementia
US20070060604A1 (en) * 2002-03-25 2007-03-15 Council Of Scientific And Industrial Research Antibiotic pharmaceutical composition with lysergol as bio-enhancer and method of treatment

Also Published As

Publication number Publication date
WO2014195849A2 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
HK1206021A1 (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
WO2014174425A3 (en) Compositions and methods for the treatment of orthostasis and neurological diseases
WO2013175376A3 (en) Compositions and methods for the treatment of local pain
MX386467B (en) Compositions and methods for the treatment of xerostomia
WO2014068463A3 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
WO2014091384A3 (en) Compositions and methods for the treatment of mucositis
WO2016046680A3 (en) Compositions and methods for the treatment of liver metabolic diseases
MX2022005523A (en) Compositions and methods for the treatment of fungal infections.
MX2017013099A (en) Methods for the treatment of inflammatory disorders.
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
WO2014087323A3 (en) Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases
WO2014006529A3 (en) Compositions and methods for the treatment of moderate to severe pain
WO2013167998A3 (en) Compositions and methods for the treatment of autonomic and other neurological disorders
MX383090B (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORAL INFECTIOUS DISEASES.
WO2014097137A3 (en) Compositions and methods for the treatment of seizures and neurologic diseases
WO2014195850A3 (en) Compositions and methods for the treatment of neurologic diseases and neurological disorders
WO2014195849A3 (en) Compositions and methods for the treatment of cerebrovascular diseases
WO2015028976A3 (en) Compounds and methods for the treatment of inflammatory diseases
WO2013175344A3 (en) Compositions and methods for treatment of peridontitis and rheumatoid arthritis
WO2013167989A3 (en) Compositions and methods for the treatment of neurological disorders
MX386208B (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS.
WO2014118649A3 (en) Compositions and methods for the treatment of cardiovascular diseases
WO2017208088A3 (en) Compositions and methods for the treatment of parkinson's disease

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 14807680

Country of ref document: EP

Kind code of ref document: A2